• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    John Wiley & Sons (WLY) Could Be 25% Undervalued On New Open Access Journals

    Simply Wall St·11/01/2026 12:35:47
    語音播報

    John Wiley & Sons (WLY) has expanded its Advanced Portfolio by adding four new open access journals focused on cities, food systems, microbiome research, and psychology. The collection now includes 36 multidisciplinary titles.

    For context, John Wiley & Sons’ share price has eased 0.5% over the last day and slipped 5.1% over the week, yet it still carries a 7.7% 1 month share price gain and a 73.5% year to date share price return, alongside a 43.7% 1 year total shareholder return. This points to strong longer term momentum even as enthusiasm cools slightly in the very near term.

    Spot opportunities beyond John Wiley & Sons by screening for research focused publishers and content platforms with resilient fundamentals in the 19 high quality undiscovered gems.

    After a sharp year to date climb, John Wiley & Sons still trades at a sizeable gap to both analyst targets and estimated fair value. Is that discount a warning sign or an opening for patient investors?

    Most Popular Narrative: 25% Undervalued

    John Wiley & Sons closed at $51.17, while the most followed narrative pegs fair value at $68 based on a discounted cash flow view using a 7.41% required return. That gap frames the entire debate around whether Wiley’s pivot into open access and AI related services can support the cash generation implied by that higher valuation.

    Strong growth in Open Access and digital research publishing, reinforced by multiyear renewal agreements and expanding global submissions (up 19%), positions Wiley to capture increasing demand for scalable, reputable research content, supporting sustained revenue growth and high-margin recurring revenues.

    See why 4 investors see John Wiley & Sons as 25% undervalued.

    Result: Fair Value of $68 (UNDERVALUED)

    Still, pressure on traditional subscriptions from open access models and uncertainty around future AI licensing demand could quickly weaken the case for John Wiley & Sons’ assumed upside.

    Find out about the key risks to this John Wiley & Sons narrative.

    Next Steps

    Mixed messages in the John Wiley & Sons story so far, right? Act while the debate is fresh and weigh both sides by reviewing the 5 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond John Wiley & Sons?

    Do not stop with John Wiley & Sons. Broaden your watchlist with fresh opportunities that match your risk, income, and balance sheet preferences using focused screeners.